On April 22, 2024 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, reported that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic "off-the-shelf" gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT (Free ASGCT Whitepaper) 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD (Press release, Adicet Bio, APR 22, 2024, View Source [SID1234642226]). The oral presentation will take place on May 10, 2024 in the Targeted Gene and Cell Therapy session, co-chaired by Adicet Bio’s Chief Scientific Officer, Blake Aftab, Ph.D.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing new preclinical data at ASGCT (Free ASGCT Whitepaper) further illustrating ADI-270’s robust anti-tumor activity with a differentiated method for targeting CD70 across multiple solid and hematologic cancers," said Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. "ADI-270 is a next-generation CAR T cell therapy candidate designed to capitalize on potent tumor infiltration associated with the gamma delta T cell platform. ADI-270 is further enhanced with armoring to address suppressive tumor microenvironments and to address clearance by host T cells. In preclinical studies, ADI-270 demonstrated enhanced functional persistence and potency, including unique contribution of innate anti-tumor immunity, compared to multiple clinically relevant benchmarks in cancers expressing CD70. Supported by these encouraging data, we look forward to advancing ADI-270’s clinical development and remain on track to file an IND in renal cell carcinoma this quarter."

Findings from this study have further characterized and have provided comparative benchmarking for the mechanisms by which ADI-270 provides enhanced functionality and potency in CD70 positive expressing tumors such as clear cell renal cell carcinoma (ccRCC) and facilitates a robust anti-tumor effect that supports its continued development. The preclinical findings indicate:

ADI-270 demonstrated potent in vitro cytotoxicity against multiple CD70 positive tumor cell lines expressing varying levels of CD70.
ADI-270 demonstrated robust cytotoxicity against heterogeneous CD70 negative and CD70 positive tumor cell cultures, highlighting the potential of gamma delta CAR T cells to be effective against tumors with mixed antigen expression.
ADI-270’s unique use of CD27-based targeting of CD70 demonstrated robust CAR-mediated killing in multiple cancer models including ccRCC, non-small cell lung cancer and T cell lymphoma, and including those models with lower levels of CD70 expression.
ADI-270 inhibited tumor growth in the context of suppressive tumor microenvironment attributed to inclusion of dominant-negative transforming growth factor beta receptor and demonstrated resilience to clearance by host T cells attributed to the function of CD27-based CAR targeting of CD70 also expressed on host T cells.
Robust anti-tumor effects in an in vivo model of ccRCC, such as tumor infiltration, proliferation, and effector function, were observed after administration, resulting in eradication of CD70 positive tumor cells.
Details for the oral presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Oral Session: Targeted Gene and Cell Therapy Session I
Presenting Author: Shon Green, Ph.D.
Date & Time: May 10, 2024 at 5:00 PM EST

On April 22, 2024 ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, reported an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland (Press release, ReNAgade Therapeutics, APR 22, 2024, View Source [SID1234642225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to highlight foundational research and development advancements at ASGCT (Free ASGCT Whitepaper) supported by our poster presentation illuminating ReNAgade’s continued work in validating our immune tropic LNP-based delivery systems in NHPs with broad potential applications in oncology and autoimmune diseases," said Pete Smith, Ph.D., Chief Scientific Officer of ReNAgade. "Additionally, our oral presentation demonstrates a non-viral, all-RNA gene editing system enabling in vivo, exon-sized insertion and probable re-dosing with the goal of higher specificity and a better safety profile when used in the clinical setting. Together, these promising data are another important step in our efforts to innovate beyond the current limitations of RNA medicine."

Key Highlights from the Abstracts:

Employed a systematic barcoding screening approach to evaluate and identify engineered lipid nanoparticles (LNP) from a library of 200+ LNPs across multiple structural and chemically distinct classes of ionizable, helper, structural, and hydrophilic lipids. Lead LNP candidate demonstrated ~60% delivery efficiency in total splenic T cells and ~80% delivery efficiency in peripheral blood T cells in non-human primate models.
Improved retron-mediated target insertion through a combination of retron reverse transcriptase (RT) engineering, non-coding RNA (ncRNA) minimization, chemical modification, and homology-dependent repair manipulation. Combination of retron system optimization and ncRNA engineering led to 2-fold higher 305 base pair insertion and ~40% editing efficiency in hematopoietic stem cells.
ASGCT Annual Meeting Presentation Details:

TITLE: "Retron Mediated Exon-Sized Genome Insertion Using an All-RNA System"
SESSION TITLE: New Technologies for Gene Targeting and Gene Correction
PRESENTATION TYPE: Oral
ABSTRACT NUMBER: 14
PRESENTER: Inna Shcherbakova, Ph.D., Senior Director, Platform, ReNAgade Therapeutics
DATE AND TIME: Tuesday, May 7, 2024, from 2:15 p.m. – 3:30 p.m. ET

TITLE: "Novel Immune Tropic LNP-Based mRNA Delivery in Non-Human Primates"
SESSION TITLE: Wednesday Posters: Other Nonviral Delivery
PRESENTATION TYPE: Poster
ABSTRACT NUMBER: 749
PRESENTER: Juliet Crabtree, Ph.D., Associate Principal Scientist, ReNAgade Therapeutics
DATE AND TIME: Wednesday, May 8, 2024, at 12:00 p.m. ET

On April 22, 2024 Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival through early detection, today announced its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study (Press release, Immunovia, APR 22, 2024, View Source [SID1234642224]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the study, Immunovia’s next-generation test demonstrated specificity of 98 percent and sensitivity of 75 percent in detecting early stage (1 and 2) pancreatic ductal adenocarcinoma (PDAC), a very aggressive and the most common form of pancreatic cancer. The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Importantly, these results confirm the technical advancement of the next-generation test over Immunovia’s first-generation test, IMMray PanCan-d. The next-generation test includes high-performing protein biomarkers, making the test less reliant on CA19-9. This is a major achievement as around 10 percent of patients, including many patients of African ancestry, do not produce CA19-9, so the IMMray PanCan-d test could not be used in those patients. The results with the new test were achieved including PDAC patients with low CA19-9 values.

Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer. With the first-generation Immunovia test, IMMray PanCan-d, about 10 percent of patients received a test result of "borderline", creating indecision for clinicians.

The next-generation test is now established on a broadly used ELISA platform, resulting in more precise protein measurement, faster testing, and lower cost of goods sold.

"Pancreatic cancer is a brutal and lethal cancer. People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early. We are very excited about the potential of our test to meet this need and increase survival rates for these patients," says Jeff Borcherding, CEO and President of Immunovia.

The model development study was designed to select the highest performing biomarkers to include in the next-generation test, to define the algorithm to produce a diagnostic result, and to provide an initial assessment of the test’s clinical performance. The study included 481 blood samples from the U.S. and Europe. Of these, 133 were samples from patients with stage 1 or 2 PDAC. The 348 control samples represented a wide range of subjects, including people at high-risk for hereditary and familial pancreatic cancer, diabetics, patients with benign pancreatic lesions worrisome for PDAC, and healthy individuals.

Immunovia will now move to a second phase of the model development study, expected to be completed in 6 – 8 weeks, in which it will conduct additional statistical analyses to refine and assess the robustness of the test model. In addition, test performance will be evaluated in a more selective cohort of patients at high risk for pancreatic cancer.

In the second and third quarters of 2024, Immunovia will perform several analytical validation steps to verify the accuracy and reproducibility of the protein biomarker measurements. In the fourth quarter of 2024, the company will conduct a large clinical validation study to confirm the performance of the next-generation test, setting the stage for a U.S. launch in 2025.

Immunovia estimates that there are at least 600,000 individuals in the U.S. at high risk of pancreatic cancer due to family history and genetic mutations. Many more are at risk due to other factors. The current standard of care for surveillance is annual imaging using magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS). High-risk individuals and clinicians at leading high-risk pancreatic cancer surveillance centers have expressed a very strong desire for a simple blood test to make surveillance faster, more convenient, and less invasive.

On April 22, 2024 Hyundai Bioscience (KOSDAQ 048410) reported the positive results from its preclinical study on triple-negative breast cancer, investigating combination therapy of ‘Niclosamide-based oral anti-cancer drug’ jointly developed with CNPharm and Docetaxel, one of widely-used chemical anticancer agents (Press release, Hyundai Bioscience, APR 22, 2024, View Source [SID1234642222]). As a result, the combination therapy was found to be more effective than Docetaxel alone. The anti-cancer efficacy of the combination therapy group was 67% better than the Docetaxel-treated group.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This preclinical study results will be published through an SCI-level paper.

Hyundai Bioscience has succeeded in repurposing Niclosamide as an oral anticancer drug. Niclosamide had been found effective in treating various cancers by acting on the metabolic process of cancer cells, evidenced by decades of in vitro studies.

Metabolic anticancer drugs inhibit the growth and survival of cancer cells by disrupting the unique metabolic mechanisms of cancer cells as well as blocking the cell signaling pathways. Metabolic anticancer agents exhibit higher antitumor activity when treated with the existing anticancer drugs as a combination therapy.

From the in vitro test, Niclosamide successfully inhibited the proliferation and survival of cancer cells by disrupting their metabolism, preventing the anticancer drug-resistance by blocking the cell signaling pathways of tumor cells and recurrence and metastasis of cancer by inhibiting cancer stem cells. Niclosamide is found to be an antitumor agent that blocks metabolism, and Niclosamide-based anticancer drugs can solve the resistance and metastasis problems simultaneously.

Due to its anticancer mechanism, Niclosamide is effective against multiple cancers, including lung cancer, breast cancer, prostate cancer, colon cancer, liver cancer, kidney cancer, and head and neck cancer. It has also been found to be highly effective against cancers that are resistant to current anticancer treatments such as triple-negative breast cancer, lung cancer, prostate cancer, ovarian cancer, colon cancer, pancreatic cancer, and head and neck cancer.

Although Niclosamide was known for excellent anticancer efficacy, it has not been clinically used on humans for over 60 years because of its ‘low bioavailability’ and ‘short half-life to maintain effective drug concentration in the blood.’

Through its proprietary ‘drug delivery technology’ technology, Hyundai Bioscience, in collaboration with CNPharm, has developed a niclosamide-based oral anticancer drug formulation that enables a drug concentration at IC50 level or higher to inhibit the proliferation of cancer cells even with a non-toxic Niclosamide dose. Their 3-month-long in vivo toxicity tests demonstrated that the Niclosamide blood concentration level of no-observed-adverse-effect level (NOAEL) dose was 7,888 ng/mL. Considering the IC50 of various cancer cells is mostly 65~654 ng/mL, Niclosamide can effectively inhibit cancer cell proliferation even when administered at a dose less than one-tenth of the NOAEL.

Hyundai Bioscience’s in vivo efficacy study on combination therapy of a niclosamide-based anticancer agent with Docetaxel was conducted on animals implanted with triple-negative breast cancer cells. The results confirmed that Niclosamide significantly increased the anticancer efficacy.

Dr. Jin Geun-Woo, leading Hyundai Bioscience R&D, highlighted the significance of these preclinical results, stating, "This is the first case that is statistically proven in vivo that the oral Niclosamide-based anticancer treatment has a remarkable effect on triple-negative breast cancer, a type of cancer that is challenging to treat. Niclosamide-based metabolic anticancer drugs could potentially address the problems of drug resistance and metastasis that make cancer treatment difficult." He added, "Clinical phase 1/2a trials will be conducted in Korea for various difficult-to-treat cancers, including triple-negative breast cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and metastatic prostate cancer."

Mr. Oh Sang-gi, the CEO of Hyundai Bioscience, announced, "The Niclosamide-based oral anticancer drug project will be carried out by a new subsidiary of Hyundai Bioscience, ADM KOREA," and added, "Hyundai Bioscience therefore plans to transfer its Niclosamide-based oral anticancer technology to its new subsidiary."

On April 22, 2024 ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, reported that it will present new ex vivo preclinical data for ImmPACT Bio’s bispecific Claudin 18.2 (CLDN18.2)/TGF-β chimeric antigen receptor (CAR) T program for the treatment of solid tumors that express CLDN18.2, including gastric and gastroesophageal junction cancer, as part of a poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 27th Annual Meeting, taking place in Baltimore, MD from May 7-11, 2024 and virtually (Press release, ImmPACT-Bio, APR 22, 2024, View Source;car-t-program-at-the-american-society-of-gene–cell-therapy-27th-annual-meeting-302123539.html [SID1234642221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is a significant unmet medical need in patients with gastric cancer, which is among the top three deadliest cancers globally. CLDN18.2 has emerged as a promising target due to its elevated expression in tumor cells but not healthy cells. Previous CAR T-cell therapies targeting CLDN18.2 have demonstrated promise but lacked durability, likely due to poor T-cell persistence and function in solid tumors," said Sumant Ramachandra, M.D., Ph.D., chief executive officer of ImmPACT Bio. "We are using a novel bispecific approach designed to enhance CAR T-cell activity in solid tumors by overcoming immune suppression in the tumor microenvironment. We will present new ex vivo preclinical data at ASGCT (Free ASGCT Whitepaper) which demonstrated the ability of our bispecific CAR targeting CLDN18.2 and TGF-β to convert the immunosuppressive TGF-β signal into a T-cell activation signal to ultimately enhance T-cell fitness, reduce regulatory T-cell conversion, and decrease phenotypic exhaustion."

Details for the presentation are as follows:

Title: Engineering a Bispecific Claudin 18.2/TGF-β CAR to Target Claudin 18.2 Positive Tumors and Overcome the Tumor Microenvironment
Abstract Number: 832
Presenter: Jessica Reyes, ImmPACT Bio
Poster Session Date/Time: Wednesday, May 8, 2024 at 12:00 – 7:00 PM ET
Author Reception Date/Time: Wednesday, May 8, 2024 at 5:30 – 7:00 PM ET
Poster Session: Immune Targeting and Approaches with Genetically Modified Cells and Cell Therapies

Abstracts and additional details can be found at the ASGCT (Free ASGCT Whitepaper) 27th Annual Meeting website.